Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The medical examination software provider doubled the size of a round that includes Qualcomm Ventures along with its valuation.

Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.

Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Returning investor Leaps by Bayer was among the participants in the cell-based immunotherapy developer’s series C round having previously led a $250m round in 2019.

Heritage Medical Systems and AbbVie Ventures took part in genome editing technology developer Caribou Biosciences' first funding round in five years.

Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.

Biox Biosciences, Novo, Sanofi and Merck & Co are all in line to exit the immuno-oncology therapy developer, which has filed for a $100m initial public offering.

UC Berkeley-founded genome editing technology developer Caribou Biosciences has completed its first funding round in five years.